We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SEC Subpoenas Fibrogen Over Falsified Heart Safety Data for Anemia Drug
SEC Subpoenas Fibrogen Over Falsified Heart Safety Data for Anemia Drug
Almost a year after admitting it manipulated safety data for its anemia drug roxadustat, Fibrogen has disclosed that the Securities and Exchange Commission (SEC) is investigating its actions.